GradedHealth

Fenugreek

Last reviewed October 2026 · Based on 16 studies

Bottom line

Fenugreek seeds modestly lower HbA1c, a long-term blood sugar test, in people with type 2 diabetes, according to several meta-analyses. Fasting blood sugar results are mixed and most trials are small. Safety data are limited: one case report links a fenugreek supplement to liver injury alongside a cancer drug.

What it helps with

  • Lowers long-term blood sugar (HbA1c) — Benefit, evidence grade C (Limited). Several meta-analyses of RCTs report HbA1c falls of 0.54 to 0.88 points; downgraded for inconsistency between trials and because HbA1c is a blood marker, not a diabetes complication.
  • Lowers fasting blood sugar — Mixed results, evidence grade C (Limited). Reviews disagree: one found a fall of 0.96 mmol/L, another no significant change; downgraded for inconsistency with high heterogeneity (I2 80%).

What it is

Fenugreek (Trigonella foenum-graecum) is an annual plant whose seeds are used in cooking and in traditional medicine for diabetes [1]. Studies use whole-seed powder, standardised extracts and defatted seed flakes [1][2].

What the research says

Meta-analyses of randomised trials show that fenugreek lowers HbA1c by about 0.54 to 0.88 percentage points [1][3][4]. Fasting blood sugar results are mixed: one review found a fall of 0.96 mmol/L [4], while another found no significant change [3]. Trials are small and vary in form and dose, so the effect size is uncertain [1].

Doses used in studies

Trials used doses from 2 g a day [5] to 10 g a day for eight weeks [6], and 25 g twice a day for one month [7]. These are study doses, not recommendations.

Safety and interactions

Side effects: mild gastrointestinal complaints were reported in some trials, and no severe adverse events were found in the 2023 meta-analysis [1]. Medicine interactions: fenugreek may add to the effect of diabetes medicines and cause low blood sugar [8]; a case report describes a probable herb-drug interaction with ribociclib and liver injury [9]. Pregnancy and breastfeeding: no trial of fenugreek in pregnancy was found; galactagogue evidence is very uncertain [10]. Upper limits and toxic doses: none were found in the trials reviewed. Kidney disease and bleeding disorders: no data were found. People with diabetes on medicines should talk to a doctor first.

Caveats and open questions

Fasting blood sugar results conflict between reviews [4][3]. Several trials are small or low quality, and one trial of 12 patients did not show a fasting glucose benefit against glibenclamide [5]. One crossover trial was funded by the company that sells its product [2]. Whether whole seed, extract or flakes works best is not settled [1].

References

  1. The Effect of Fenugreek in Type 2 Diabetes and Prediabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Int J Mol Sci, 2023.
  2. Effect of 'FenuflakesTM' on 24-hour glycemic variability in adults with type 2 diabetes: A randomized crossover continuous glucose monitoring study.. Asia Pac J Clin Nutr, 2025.
  3. Effect of Fenugreek on Hyperglycemia: A Systematic Review and Meta-Analysis.. Medicina (Kaunas), 2023.
  4. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials.. Nutr J, 2014.
  5. A randomized controlled clinical trial evaluating the effect of Trigonella foenum-graecum (fenugreek) versus glibenclamide in patients with diabetes.. Afr Health Sci, 2019.
  6. Effect of Fenugreek Seeds on Serum Metabolic Factors and Adiponectin Levels in Type 2 Diabetic Patients.. Int J Vitam Nutr Res, 2014.
  7. Antidiabetic Effect of Fenugreek Seed Powder Solution (Trigonella foenum-graecum L.) on Hyperlipidemia in Diabetic Patients.. J Diabetes Res, 2019.
  8. Natural Health Products and Diabetes: A Practical Review.. Can J Diabetes, 2017.
  9. Ribociclib-Induced hepatotoxicity exacerbated by fenugreek supplement use: A case report.. J Oncol Pharm Pract, 2025.
  10. Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.. Cochrane Database Syst Rev, 2020.